Oncolytics Biotech, Inc. (NASDAQ:ONCY) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET
Company Participants
Jon Patton - Director, IR & Communications
Matt Coffey - CEO
Kirk Look - CFO
Tom Heineman - CMO
Allison Hagerman - VP, Product Development
Conference Call Participants
Soumit Roy - Jones Research
John Newman - Canaccord
Luis Santos - H.C. Wainwright
Carvey Leung - Cantor
Operator
Good afternoon, and welcome to Oncolytics Biotech's Fourth Quarter and Full Year 2023 Conference Call. All participants are now in a listen-only mode. There will be a question-and-answer session at the end of this call. Please be advised that this call is being recorded at the company's request.
I would now like to turn the conference call over to Jon Patton, Director of Investor Relations and Communications. Please go ahead.
Jon Patton
Thank you, operator, and good afternoon, everyone.
Earlier today, Oncolytics issued a press release providing recent operational highlights and financial results for the fourth quarter and full year of 2023. A replay of today's call will be available on the Events section of the Oncolytics' website approximately two hours after its completion. After remarks from company management, we will open the call for Q&A.
As a reminder, various remarks made during this call contain certain forward-looking statements relating to the company's business prospects and the development and commercialization of pelareorep, including statements regarding the company's mission, strategy and objectives, company's belief as to the potential mechanism of action and benefits of pelareorep as a cancer therapeutic our clinical development plans for 2024, including initiation of our first registrational studies for pelareorep, manufacturing program, our cash runway, and other statements related to anticipated developments in the company's business.
These statements are based on management's current expectations and beliefs and are subject to a number of factors, which involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or expectations implied by these forward-looking statements.
In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, there can be no assurance that these statements or expectation or belief will be achieved.
These factors include results of current or pending clinical trials, risks associated with intellectual property protection, financial protections, actions by regulatory agencies and those other factors detailed in this company's filings with SEDAR and the SEC. Oncolytics does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.